Luminor anticipated to have “big impact” on Japanese market following SOL-Japan results

Yoshimitsu Soga (Fukuoka, Japan) spoke to Vascular News at the Leipzig Interventional Course (LINC) 2024 (28-31 May, Leipzig, Germany) about the SOL-Japan trial.
The interventional oncologist at Kokura Memorial Hospital and principal investigator of SOL-Japan noted that this was a drug-coated balloon (DCB) approval trial conducted at 12 Japanese institutions. It was a prospective, multicentre, single-arm, open-label trial that achieved a primary patency result of 94.4%, which Soga described as an “awesome” result.
Soga attributed this and other positive outcomes from the trial in part to the user-friendly nature of the Luminor and anticipates the device will have a “big impact” on the Japanese market in light of the trial’s findings.
This video is sponsored by iVascular.